Chargement en cours...
Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
Sorafenib a multi-target tyrosine kinase inhibitor, is the first-line drug for treating advanced hepatocellular carcinoma (HCC). Mechanistically, it suppresses tumor angiogenesis, cell proliferation and promotes apoptosis. Although sorafenib effectively prolongs median survival rates of patients wit...
Enregistré dans:
| Publié dans: | Front Oncol |
|---|---|
| Auteurs principaux: | , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8292964/ https://ncbi.nlm.nih.gov/pubmed/34307125 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.641522 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|